Adjuvant chemotherapy with gemcitabine plus erlotinib *** alone for patients with resected pancreatic ductal adenocarcinoma:is there a role for erlotinib?—review of the open label phase III trial CONKO 005

作     者：Mathilde Wisniewski Pierre-Alain Placide Sandra Granier Yacoub Al Shatti Shuaib Al Qalaf Mohamed Bouattour Michele Lamuraglia Pascal Hammel 

作者机构：Department of Digestive and Medical OncologyHopital Beaujon(AP-HP)University Denis Diderot-ParisⅦClichyFrance 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2018年第7卷第5期

页      面：399-402页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：gemcitabine patients ductal 

摘      要：Sinn et al. (1) report the results of a multicenter trial comparing the combination of gemcitabine and erlotinib with gemcitabine alone for adjuvant therapy in 436 patients who underwent R0 resection for pancreatic ductal carcinoma (PDAC).